Acamprosat: Mechanism, Dosage, Side Effects, and Clinical Role in Alcohol Dependence

Acamprosate (trade name Campral) is a pharmaceutical agent employed for relapse prevention in cases of alcohol dependence. Chemically, it constitutes calcium acetylhomotaurinate, representing a synthetic derivative of the endogenous aminosulfonic acid taurine.

Origin and Structure #

Taurine occurs extensively within the brain, functioning there as a neuromodulatory compound. Acamprosate emerged through the attachment of an acetyl group and extension of the carbon chain. Such modifications aim to enhance bioavailability while altering interactions with specific neurotransmitter systems.

Mechanism of Action #

The precise mode of action of acamprosate remains incompletely elucidated. Central to its effects is the restoration of the disrupted equilibrium between excitatory and inhibitory neurotransmitters, a characteristic imbalance following prolonged alcohol abuse (disturbed balance):

• Glutamate inhibition: Acamprosate attenuates hyperactivity within the NMDA receptor complex.
• GABA system: Evidence indicates mild GABA-agonistic properties, though markedly weaker compared to taurine.
• Overall effect: Stabilization of neuronal balance accompanied by reduction in craving.

Comparison with Taurine #

Taurine exhibits broader activity: It potentiates GABA- and glycine-mediated transmission, buffers intracellular calcium in neurons, and demonstrates antioxidant properties. Nonetheless, clinical investigations reveal no definitive benefit as an anti-craving agent.

In contrast, acamprosate proves more targeted, primarily suppressing the glutamate hyperactivity typical of alcohol-related pathology. Research indicates it outperforms taurine in managing alcohol dependence, despite possessing a narrower spectrum of action.

Clinical Application #

Numerous extensive meta-analyses confirm that acamprosate substantially lowers relapse rates following alcohol withdrawal, particularly when integrated with psychosocial support. It is regarded as well-tolerated, with diarrhea and mild gastrointestinal disturbances representing the most common adverse effects.

Frequently Asked Questions (FAQ) About Acamprosate #

Dosage Guidelines #

The standard dosage of acamprosate (Calcium acetylhomotaurinate) for maintaining abstinence in alcohol dependence is 666 mg three times daily (equivalent to two 333 mg tablets per dose), resulting in a total daily amount of 1998 mg. Administration occurs orally, preferably at mealtimes to improve gastrointestinal tolerance, though intake independent of meals remains possible. Treatment initiation should occur promptly after completion of alcohol withdrawal, ideally when the patient has attained initial abstinence. Continuation during occasional relapses is generally advisable, as abrupt discontinuation may reduce overall benefit.

Dose adjustment becomes necessary in cases of renal impairment: moderate reduction (e.g., to 333 mg three times daily) applies when creatinine clearance ranges between 30–50 ml/min. Severe renal insufficiency (creatinine clearance ≤30 ml/min) constitutes a contraindication. No dosage modification is required for mild to moderate hepatic impairment, as hepatic metabolism plays no significant role. Duration of therapy often extends over 12 months or longer, guided by individual clinical response and ongoing psychosocial support.

Side Effects #

Acamprosate exhibits a favorable tolerability profile overall. The most frequently reported adverse reaction involves gastrointestinal disturbances, particularly diarrhea, which affects a substantial proportion of users but usually remains mild to moderate and often subsides with continued administration. Additional common complaints include flatulence, nausea, abdominal discomfort, and occasional vomiting.

• Common (≥1/100 to <1/10): Diarrhea, abdominal pain, nausea, vomiting, flatulence, pruritus, maculopapular rash.
• Less common: Headache, dizziness, altered libido, impotence, anxiety, insomnia, somnolence, depression, paresthesia, syncope.
• Rare but noteworthy: Suicidal ideation or attempts, worsening of pre-existing depression (causal relationship uncertain but monitored closely), hypersensitivity reactions (rash, urticaria, angioedema), fluctuations in blood pressure, irregular heart rhythm.

Most side effects prove transient or manageable without discontinuation. Persistent or severe gastrointestinal symptoms may prompt temporary dose reduction. Any emergence of mood alterations, suicidal thoughts, or severe allergic manifestations requires immediate medical attention. Acamprosate carries no abuse potential, produces no disulfiram-like reaction upon alcohol ingestion, and shows negligible interaction with hepatic enzyme systems.

---

---